up,
Nothing clear here but these are the facts:
Avastin has never had it's own full trial for 1st line colorectal, onc's use it on "blind faith". In other words it was proven to work with IFL so it "probably" will work with folfox or folfiri.
There has been a few partial trials using Avastin with folfox and folfiri, and the results didn't seem significant and as of OCT 06 the doc's are starting to ask why.
So to answer your question, ERBY now has positive results and AVASTIN has blind faith.
Getting back to your question, "if erby was not as robust or equally as robust as Avastin how could it replace Avastin". Simply, probably 25% of the eligible 1st line mCRC patients don't take Avastin because they have hypertension,cardio or bleeding disorders and for them avastin's side effects are very dangerous. 25% of the 1st line market is worth a couple of hundred million dollars.
Now remember, Cetuximab is the ONLY biologic that has a proven benefit at this point.
